Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant Long-term Safety in Chinese Migraine Patients
NCT05371652Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rimegepant in migraine, sponsored by Pfizer. Started May 2022; status: completed.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05371652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05371652.